Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6022494 | 1.00 | CTRB1 (0.51) | CTRB1SYKELANEATMCA12 | |
| SCHEMBL6022051 | 1.00 | CTRB1 (0.51) | CTRB1SYKELANEATMCA12 | |
| SCHEMBL24012785 | 0.94 | CTRB1 (0.50) | CTRB1SYKATMCA12CA1 | |
| SCHEMBL5141850 | 0.93 | CTRB1 (0.49) | CTRB1SYKELANEATMCA12 | |
| SCHEMBL14665176 | 0.93 | CTRB1 (0.49) | CTRB1SYKELANEATMCA12 | |
| SCHEMBL5141853 | 0.93 | CTRB1 (0.49) | CTRB1SYKELANEATMCA12 | |
| SCHEMBL5141852 | 0.93 | CTRB1 (0.49) | CTRB1SYKELANEATMCA12 | |
| SCHEMBL12208730 | 0.90 | SYK (0.52) | CTRB1SYKELANEATMCA12 | |
| SCHEMBL20640409 | 0.90 | SYK (0.52) | CTRB1SYKELANEATMCA12 | |
| SCHEMBL19050929 | 0.90 | SYK (0.52) | CTRB1SYKELANEATMCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985730-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-7834021-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | INCYTE CORPORATION | 2009-10-01 | — | — | US | disclosed |
| EP-1546096-B1 | PROCESS FOR THE PREPARATION OF AMINO-PYRROLIDINE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| US-7064199-B2 | Process for the manufacture of 3-amino-pyrrolidine derivatives | BASILEA PHARMACEUTICA AG (CH) | 2006-06-20 | — | — | US | disclosed |
| EP-1546096-A1 | PROCESS FOR THE PREPARATION OF AMINO-PYRROLIDINE DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| US-6872836-B2 | Process for the manufacture of 3-amino-pyrrolidine derivatives | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2005-03-29 | — | — | US | disclosed |
| US-20040127703-A1 | Process for the manufacture of 3-amino-pyrrolidine derivatives | MULLER MARC (FR) | 2004-07-01 | — | — | US | disclosed |
| US-20040034236-A1 | Process for the manufacture of 3-amino-pyrrolidine derivatives | BASILEA PHARMACEUTICA AG (CH) | 2004-02-19 | — | — | US | disclosed |
| WO-2004013097-A1 | PROCESS FOR THE PREPARATION OF AMINO-PYRROLIDINE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127703-A1 | Process for the manufacture of 3-amino-pyrrolidine derivatives | PRMT1, PEPD, PRMT3 | CTRB1 1045/4885SYK 2763/4885ELANE 3218/4885 |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | CCR2, CXCR3, CCR5 | CTRB1 3933/4885SYK 933/4885ELANE 2932/4885 |
| US-20040034236-A1 | Process for the manufacture of 3-amino-pyrrolidine derivatives | PRMT1, PEPD, PRMT3 | CTRB1 1952/4885SYK 3844/4885ELANE 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.